VECURONIUM- vecuronium bromide injection, powder, lyophilized, for solution

Ország: Egyesült Államok

Nyelv: angol

Forrás: NLM (National Library of Medicine)

Aktív összetevők:

vecuronium bromide (UNII: 7E4PHP5N1D) (vecuronium - UNII:5438723848)

Beszerezhető a:

Sagent Pharmaceuticals

INN (nemzetközi neve):

vecuronium bromide

Összetétel:

vecuronium bromide 10 mg in 10 mL

Az alkalmazás módja:

INTRAVENOUS

Recept típusa:

PRESCRIPTION DRUG

Terápiás javallatok:

Vecuronium bromide for injection is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Vecuronium bromide is contraindicated in patients known to have a hypersensitivity to it.

Termék összefoglaló:

Vecuronium Bromide for Injection is supplied as follows: Store dry powder at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Retain in carton until time of use. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex. SAGENT™ Mfd. for SAGENT Pharmaceuticals Schaumburg, IL 60195 (USA) Mfd. by MN Pharmaceuticals Made in Turkey ©2011 Sagent Pharmaceuticals, Inc. Revised: July 2011

Engedélyezési státusz:

Abbreviated New Drug Application

Termékjellemzők

VECURONIUM- VECURONIUM BROMIDE INJECTION, POWDER, LYOPHILIZED, FOR
SOLUTION
SAGENT PHARMACEUTICALS
----------
VECURONIUM BROMIDE FOR INJECTION
SAGENT™
Rx only
THIS DRUG SHOULD BE ADMINISTERED BY ADEQUATELY TRAINED
INDIVIDUALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS, AND
HAZARDS.
DESCRIPTION
Vecuronium Bromide for Injection is a nondepolarizing neuromuscular
blocking agent of intermediate
duration, chemically designated as
1-(3α,17β-Dihydroxy-2β-piperidino-5α-androstan-16β,5α-yl)-1-
methylpiperidinium bromide, diacetate. The structural formula is:
Its chemical formula is C
H BrN O with molecular weight 637.73.
Vecuronium Bromide for Injection is supplied as a sterile nonpyrogenic
freeze-dried buffered cake of
very fine microscopic crystalline particles for intravenous injection
only. Each vial contains 10 mg or
20 mg of vecuronium bromide. In addition, each 10 mg vial contains
20.75 mg citric acid anhydrous,
16.25 mg sodium phosphate dibasic anhydrous, 97 mg mannitol (to adjust
tonicity), sodium hydroxide
and/or phosphoric acid to buffer and adjust to a pH range of 3.5 to
4.5. Each 20 mg vial contains 41.5
mg citric acid anhydrous, 32.5 mg sodium phosphate dibasic anhydrous,
194 mg mannitol (to adjust
tonicity), sodium hydroxide and/or phosphoric acid to buffer and
adjust to a pH range of 3.5 to 4.5.
CLINICAL PHARMACOLOGY
Vecuronium is a nondepolarizing neuromuscular blocking agent
possessing all of the characteristic
pharmacological actions of this class of drugs (curariform). It acts
by competing for cholinergic
receptors at the motor end-plate. The antagonism to acetylcholine is
inhibited and neuromuscular block
is reversed by acetylcholinesterase inhibitors such as neostigmine,
edrophonium, and pyridostigmine.
Vecuronium is about 1/3 more potent than pancuronium; the duration of
neuromuscular blockade
produced by vecuronium is shorter than that of pancuronium at
initially equipotent doses. The time to
onset of paralysis decreases and the duration of maximum effect
increases with increasing vecuroniu